Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2022-08-29 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and other substantive financial and operational information for the half-year period ending June 30, 2022. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes financial statements, management analysis, risk disclosures, and operational details typical of an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification letter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
2022年半年度募集资金存放和使用情况的专项报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022年半年度募集资金存放和使用情况的专项报告" which translates to "2022 Half-Year Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their deposit, usage, management, and investment of idle funds. It includes specific financial figures for the half-year period ending June 30, 2022, and discusses changes in investment projects and approvals from shareholders' meetings. The document is a comprehensive report on the use of capital raised by the company during a half-year period, including financial data and management explanations. This fits the definition of an Interim / Quarterly Report (IR), as it is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis related to fundraising and capital usage. It is not merely an announcement or certification, but a detailed report with financial figures and explanations. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-29 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's ninth board of directors' sixth meeting. It includes opinions on related party transactions, guarantees, fundraising usage, and appointment of senior management. The document references regulatory guidelines and company bylaws but does not contain financial statements or detailed financial data. It is a governance-related document focusing on board and management matters rather than a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1034 characters), and it is not an announcement of a report publication or certification, so it is not RPA or RNS.
2022-08-29 Chinese
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "启迪药业集团股份公司 2022 年半年度财务报告" which translates to "Qidi Pharmaceutical Group Co., Ltd. 2022 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2022. The report explicitly states it is a half-year report and is unaudited. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, which matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies due to new accounting standards issued by the Ministry of Finance. It explains the nature of the changes, the reasons behind them, and their impact on the company. The document does not contain financial statements or detailed financial data but rather informs stakeholders about the policy change and its implications. It is not a full annual or interim report, audit report, or earnings release. It is a regulatory announcement about accounting policy changes, which fits best under Regulatory Filings (RNS). The document length is short (1673 characters), and it is a formal announcement rather than a detailed report.
2022-08-29 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022 年半年度报告摘要" which translates to "2022 Half-Year Report Summary." It contains financial data and performance metrics for the half-year period, including revenue, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive details. The length is 2477 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. H1 2022
2022-08-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.